Iressa adverse events

IRESSA news. Recent knowledge and insight into IRESSA (gefitinib) 12212014018332IRESSA (getfitinib) is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer

General Information. Iressa is an anticancer drug that inhibits an enzyme (tyrosine kinase) present in lung cancer cells, as well as other cancers and normal tissues

Iressa (gefitinib) Tablets is a chemotherapy medication used to treat non-small cell lung cancer. It is available in generic form. Common side effects of Iressa Gefitinib (INN, f t n b , trade name Iressa, marketed by AstraZeneca and Teva), is a drug used for certain breast, lung and other cancers Iressa official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more

IRESSA (gefitinib) News

Official site of IRESSA (gefitinib), indicated in Europe for the treatment of adults with locally advanced or metastatic NSCLC with activating mutations of EGFR-TK 1. Anticancer Drugs. 2006 Apr17(4):401-9. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in

IRESSA (gefitinib) Tablets Special Populations: In population based data analyses, no relationships were identified between predicted steady Gefitinib reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI)